Biogen Corp (BIIB) - Biznesning o‘zini qoplash muddati
Biogen Inc. (BIIB) patent risklarini kamaytirish uchun o'zining biosimilar portfelini kengtirmoqda. Molekulyar tahlilga AI integratsiyasi orqali dori vositalarini ishlab chiqish jarayoni tezlashmoqda. Kompaniyaning o'rtacha og'irlikka ega P/E ko'rsatkichi ushbu tendentsiyalarni aniq tasdiqlaydi va joriy daraja 106.70 atrofida shakllangan. Biroq, Altsgeymer terapiyasini targ'ib qilishning yuqori xarajatlari operatsion marjaning o'sishini vaqtincha cheklamoqda.
Biogen Inc. kompaniyasining tahliliy kesimlari
- kotirovkalar va tahlilchilar prognozi:
- bozor kapitallashuvi ko'rsatkichlari:
- balans kapitallashuvi bo'yicha ma'lumotlar:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Biogen Inc.|BIIB - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati ko'rsatkichi Biogen Idec|BIIB - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Biogen Inc.|BIIB - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz hajmi Biogen|Shoshilinch likvidlik koeffitsiyenti biogen.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
BIIB - Sof foyda|Kelajakdagi foyda Biogen Inc.|BIIB - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Biogen Inc|BIIB - PEG multiplikatori|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati Biogen Inc.|BIIB - EBITDA operatsion foydasi|So'nggi to'rtta chorak uchun bir aksiya uchun sof foyda Biogen|BIIB - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik o'zgarishi biogen.com|BIIB - Joriy yilda foyda o'sishi|Keyingi yil uchun bir aksiya uchun sof foyda o'sishi prognozi Biogen Inc.
Kompaniyaning umumiy tahlili:biogen.com - BIIB
Biogen Inc. neyrodegeneratsiya sohasidagi ishlanmalarining gumanitar maqomi tufayli tashqi zarbalarga yuqori chidamlilikka ega. P/E koeffitsiyenti joriy aksiya narxini yillik sof foyda bilan solishtirish orqali ushbu ustunlikning bozor qiymatini miqdoriy baholaydi. Ushbu koeffitsient investitsiyalarning qoplanish muddatini va kelajakdagi o'sish uchun to'lanadigan premiumni belgilaydi. Narx-foyda tendentsiyasini tahlil qilish orqali investor emitentning fundamental kuchini qisqa muddatli spekulyatsiyadan ajratib olishi mumkin.
Muhim raqobatchilar
Narxning foydaga nisbati NBIX|P/E multiplikatori RGC|Biznesning o‘zini qoplash muddati Axsome|Narxning foydaga nisbati ACADIA Pharmaceuticals Inc ACAD|Xenon Corp (XENE) - Kapitalizatsiyaning foydaga nisbati|Viking Therapeutics - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti supernus.com (SUPN)|CPRX: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Denali (DNLI)|Narxning foydaga nisbati Harmony Pharma|Narx-foyda multiplikatori BHVN (Biohaven Corp)|Narx-foyda koeffitsiyenti AMLX (Amylyx Pharmaceuticals)|TRVI (trevitherapeutics.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori PRAX (Praxis Precision Medicines, Inc.)|Biznesning o‘zini qoplash muddati Anavex (AVXL)|CBLL - Narxning foydaga nisbati|PRTA (Prothena Corporation) - Narx-foyda multiplikatori|ALEC: P/E multiplikatori|Narx-foyda koeffitsiyenti annexonbio.com|Narx-foyda koeffitsiyenti OMER|Neurogene Inc (NGNE) - Biznesning o‘zini qoplash muddati|P/E multiplikatori ACIU|Narxning foydaga nisbati VYGR (Voyager Corp)|P/E multiplikatori NMRA (Neumora Therapeutics)|Biznesning o‘zini qoplash muddati scilexholding.com (SCLX)|Tevogen Bio - P/E multiplikatori|Biznesning o‘zini qoplash muddati Alpha Cognition ACOG|CGTX: P/E multiplikatori|IKT (Inhibikase Pharma) - Narxning foydaga nisbati|Narxning foydaga nisbati Cassava Sciences, Inc.|Narx-foyda multiplikatori ASRT (Assertio Therapeutics)|P/E multiplikatori COYA|VTGN - Kapitalizatsiyaning foydaga nisbati|Ovid Therapeutics - Narx-foyda koeffitsiyenti|P/E multiplikatori Acumen Pharmaceuticals, Inc ABOS|CRVO - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati ATHE (Alterity Therapeutics)|clene.com (CLNN) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati PepGen (PEPG)|JUNS (Jupiter Neurosciences) - P/E multiplikatori|Narxning foydaga nisbati RLMD|P/E multiplikatori ANVS|Biznesning o‘zini qoplash muddati gracetx.com|Narxning foydaga nisbati Firefly Neuroscience AIFF|ANEW Medical (KLTO) - Kapitalizatsiyaning foydaga nisbati|NeuroSense Therapeutics, Ltd. - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Reviva Pharmaceuticals, Inc. (RVPH)|MTVA: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati neuraxis.com (NRXS)|Narxning foydaga nisbati Helius Medical Technologies, Inc.|Narx-foyda multiplikatori PASG (Passage Bio Corp)|Narx-foyda koeffitsiyenti NEUP (Neuphoria Therapeutics Inc.)|NERV (Minerva) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ATHA (Athira Pharma, Inc.)|Biznesning o‘zini qoplash muddati addextherapeutics.com (ADXN)|ALZN - Narxning foydaga nisbati|CYCN (Cyclerion Therapeutics) - Narx-foyda multiplikatori|PTIX: P/E multiplikatori|Narx-foyda koeffitsiyenti Pasithea Therapeutics Corp.|Narx-foyda koeffitsiyenti CRGT|avenuetx.com (ATXI) - Biznesning o‘zini qoplash muddati|P/E multiplikatori BCLI|Narxning foydaga nisbati CARA (Cara Therapeutics Inc.)|P/E multiplikatori CHRO (Chromocell Therapeutics Corporation)|Biznesning o‘zini qoplash muddati Eliem Therapeutics, Inc. (ELYM)|Intra-Cellular - P/E multiplikatori|Biznesning o‘zini qoplash muddati longboardpharma.com LBPH|MRNS: P/E multiplikatori|NKGN (NKGen Biotech Inc) - Narxning foydaga nisbati|Narxning foydaga nisbati NeuroBo|Narx-foyda multiplikatori SAGE (Sage Therapeutics Inc)|P/E multiplikatori SNPX|TRVN - Kapitalizatsiyaning foydaga nisbati|Vigil Neuroscience, Inc. - Narx-foyda koeffitsiyenti|P/E multiplikatori anewmeds.com WENA|CERE - Narxning foydaga nisbati
